Catalyst Wire Dossier Catalyst Wire Dossier

Pataday 0.2% (olopatadine)

olopatadine · Alcon Research
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pataday 0.2% (olopatadine), covering 2012-09-18 to 2012-09-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis [Phase 4]

See pricing